Results 41 to 50 of about 2,622 (152)
Pyruvate kinase deficiency (PKD) is an autosomal recessive disorder caused by mutations in the PKLR gene. PKD-erythroid cells suffer from an energy imbalance caused by a reduction of erythroid pyruvate kinase (RPK) enzyme activity. PKD is associated with
Sara Fañanas-Baquero +16 more
doaj +1 more source
Novel mutations associated with pyruvate kinase deficiency in Brazil
Background: Pyruvate kinase deficiency is a hereditary disease that affects the glycolytic pathway of the red blood cell, causing nonspherocytic hemolytic anemia.
Maria Carolina Costa Melo Svidnicki +9 more
doaj +1 more source
Erythrocyte Pyruvate Kinase Deficiency mutation identified in multiple breeds of domestic cats
Background Erythrocyte pyruvate kinase deficiency (PK deficiency) is an inherited hemolytic anemia that has been documented in the Abyssinian and Somali breeds as well as random bred domestic shorthair cats.
Grahn Robert A +4 more
doaj +1 more source
The variable manifestations of disease in pyruvate kinase deficiency and their management
Pyruvate kinase deficiency (PKD) is the most common cause of chronic hereditary non-spherocytic hemolytic anemia and results in a broad spectrum of disease.
Hanny Al-Samkari +9 more
doaj +1 more source
Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik +3 more
wiley +1 more source
Gene therapy is revolutionizing treatment paradigms for haemoglobinopathies, establishing a translational framework for disorders that impact red blood cell development. In their paper, Joshi et al. describe the preclinical and early clinical landscape of gene therapies for non‐haemoglobinopathy erythroid disorders and highlight common thematic ...
Gaurav Joshi +3 more
wiley +1 more source
Background and Purpose Lobeglitazone is a thiazolidinedione and PPARγ agonist that improves metabolic parameters and hepatic steatosis, but its mechanisms are not fully understood. This study investigated the effects of lobeglitazone on hepatic transcriptomic and metabolic profiles in a rat model of obesity and Type 2 diabetes mellitus.
Hyekyung Yang +6 more
wiley +1 more source
Metabolic associated fatty liver disease (MAFLD) is associated with obesity, type 2 diabetes mellitus, and other metabolic syndromes. Farnesoid X receptor (FXR, NR1H4) plays a prominent role in hepatic lipid metabolism. This study combined the expression
Yongqiang Ma +16 more
doaj +1 more source
Abstract Loss of ovarian hormones (i.e., menopause) leads to negative effects on metabolic health. While exercise offers significant benefits, it seems to be insufficient to completely reverse these changes. The mechanisms by which exercise conveys the effects throughout the body are still poorly understood.
Veera Puumalainen +7 more
wiley +1 more source
ABSTRACT Background Circulating mitochondrial DNA is being investigated as a liquid‐biopsy biomarker because of its high copy number and release during cellular stress. However, diagnostic estimates vary across tumor types and assays, and prognostic studies have measured both cell‐free mtDNA and cellular blood‐derived mtDNA, which are not analytically ...
Ziying Zhang +5 more
wiley +1 more source

